Cosmo Pharmaceuticals N.V (C43) — Cash Flow Quality Index
Cosmo Pharmaceuticals N.V (C43) has a Cash Flow Quality Index of 1.60x as of June 2022. Operating cash flow of €6.28 Million exceeds net income of €3.94 Million, indicating high earnings quality where cash backs reported profits. Also explore Cosmo Pharmaceuticals N.V total assets for the complete picture of this company's asset base.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cosmo Pharmaceuticals N.V Cash Flow Quality Index (2016–2024)
Historical Cash Flow Quality Index for Cosmo Pharmaceuticals N.V across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check C43 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Cosmo Pharmaceuticals N.V (2016–2024)
Year-by-year earnings quality comparison for Cosmo Pharmaceuticals N.V. For live market cap and the full company financial profile, see Cosmo Pharmaceuticals N.V (C43) market capitalisation.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.22x | €162.41 Million | €133.24 Million | ▼ -95.8% |
| 2023 | 29.31x | €33.62 Million | €1.15 Million | ▲ +1419.7% |
| 2022 | 1.93x | €33.23 Million | €17.23 Million | ▲ +231.5% |
| 2021 | 0.58x | €12.61 Million | €21.67 Million | ▼ -48.1% |
| 2016 | 1.12x | €21.69 Million | €19.34 Million | — |